Allergic reactions to vaccine components

Hyeon-Jong Yang

doi:10.4168/aard.2014.2.3.157

Journal List > Allergy Asthma Respir Dis > v.2(3) > 1059019

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Yang: Allergic reactions to vaccine components

Review

Allergy, Asthma & Respiratory Disease 2014; 2(3): 157-164.

Published online: 31 July 2014

DOI: https://doi.org/10.4168/aard.2014.2.3.157

Allergic reactions to vaccine components

Hyeon-Jong Yang

Department of Pediatrics, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.

Correspondence to: Hyeon-Jong Yang. Department of Pediatrics, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, 59 Daesagwan-ro, Yongsan-gu, Seoul 140-743, Korea. Tel: +82-2-709-9345, Fax: +82-2-709-9083, ilove902@hanmail.net

Received 14 November 2013 Revised 23 December 2013 Accepted 27 December 2013

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).

Abstract

Vaccine contains active components, adjuvants, stabilizers, preservatives, and trace components. Adverse reactions to vaccines are rarely reported. However, all of vaccine components may elicit adverse reaction including life-threatening event in susceptible individuals, therefore raising concerns regarding safety of vaccine still continue up to date. Hypersensitivity reaction to vaccines can be classified as allergic reaction to the vaccine component, pseudo-allergic reaction, and exacerbation of allergic diseases. Hypersensitivity reactions to vaccine components rarely occurred in the population-level, while severe hypersensitivity reaction such as anaphylaxis may be consequent result in susceptible individuals. Some of components such as ovalbumin, gelatin, yeast, and latex were considered as common causes of allergic reactions to the vaccine. However, the incidence or causes of vaccine related hypersensitivity reaction in Korea were not well known. The aims of this article are to review the literatures with hypersensitivity reactions related with vaccine components, to provide detailed information about major components of vaccines commonly used in Korea, and to provide the best way of vaccination in susceptible individuals.

Keywords: Anaphylaxis, Hypersensitivity, Vaccines, Korea

Figures and Tables

Table 1

Components of vaccine

Table 2

Aluminum containing vaccines in Korean market

DTaP, diphtheria-tetanus-acellular pertussis; Td, tetanus diphtheria; TdaP, tetanus-diphtheria-pertussis; IPV, inactivated Polio virus; HPV, human papillomavirus; JEV, Japanese encephalitis virus.

Table 3

Gelatin or polysorbate 80 containing vaccines in Korean market

MMR, measles-mumps-rubella; JEV, Japanese encephalitis virus; HPV, human papillomavirus.

Table 4

Trace components containing vaccines in Korean market

MMR, measles-mumps-rubella; IPV, inactivated Polio virus; DTaP, diphtheria-tetanus-acellular pertussis; HPV, human papillomavirus.

Table 5

Reported cases with allergic reactions in a total of 3,705 notified vaccine-adverse reactions in Korea, 2008-2012

DTaP, diphtheria-tetanus-acellular pertussis; IPV, inactivated Polio virus; JEV, Japanese encephalitis virus; MMR, measles-mumps-rubella; Hib, Haemophilus influenzae type B; HAV, hepatitis A virus; Td, tetanus diphtheria; HBV, hepatitis B virus; BCG, Bacillus Calmette-Guerin; HPV, human papillomavirus.

Table 6

Reported cases with anaphylaxis in a total of 3,705 notified vaccine-adverse reactions in Korea, 2008-2012

Table 7

Reported cases of allergic reactions and anaphylaxis following vaccination in Korea, 2011

References

1. Wood RA, Berger M, Dreskin SC, Setse R, Engler RJ, Dekker CL, et al. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics. 2008; 122:e771–e777.

2. Busse JW, Morgan L, Campbell JB. Chiropractic antivaccination arguments. J Manipulative Physiol Ther. 2005; 28:367–373.

3. Ruggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007; 25:5675–5684.

4. Fritsche PJ, Helbling A, Ballmer-Weber BK. Vaccine hypersensitivity-update and overview. Swiss Med Wkly. 2010; 140:238–246.

5. Kim BY, Kim DH, Lee HJ, Jung SK, Li XS, Go UY, et al. Investigation on the frequency and severity of common adverse reactions of Japanese encephalitis Vaccines. Korean J Pediatr Infect Dis. 2009; 16:183–190.

6. Shin WJ, Kim SY, Ahn YM. Follow-up study of children with egg allergy : comorbidity of allergic diseases and factors affecting prognosis. Pediatr Allergy Respir Dis. 2004; 14:87–96.

7. Lee K, Lee S. Two children with egg allergy who developed systemic side reaction with MMR vaccine. Pediatr Allergy Respir Dis. 1998; 8:280–285.

8. Zent O, Arras-Reiter C, Broeker M, Hennig R. Immediate allergic reactions after vaccinations--a post-marketing surveillance review. Eur J Pediatr. 2002; 161:21–25.

9. The Korean Pediatric Society. Immunization guideline. 7th ed. Seoul: The Korean Pediatric Society;2012. p. 7–8.

10. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010; 59(RR-8):1–62.

11. Roh EJ, Chung EH, Kim JK. Quantitative analysis of egg protein by ELISA in distributed influenza vaccine in Korea. Pediatr Allergy Respir Dis. 2009; 19:345–353.

12. Kelso JM, Greenhawt MJ, Li JT, Nicklas RA, Bernstein DI, Blessing-Moore J, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012; 130:25–43.

13. Lee DH, Shin SS, Jun BY, Lee JK. National level response to pandemic (H1N1) 2009. J Prev Med Public Health. 2010; 43:99–104.

14. Kim SY, Cho J, Cha SH, Bae CW. Current status of production and market of human vaccine products in Korea. Clin Exp Vaccine Res. 2013; 2:120–127.

15. Babl FE, Lewena S, Brown L. Vaccination-related adverse events. Pediatr Emerg Care. 2006; 22:514–519.

16. Rona RJ, Keil T, Summers C, Gislason D, Zuidmeer L, Sodergren E, et al. The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol. 2007; 120:638–646.

17. Sicherer SH. Epidemiology of food allergy. J Allergy Clin Immunol. 2011; 127:594–602.

18. Ross MP, Ferguson M, Street D, Klontz K, Schroeder T, Luccioli S. Analysis of food-allergic and anaphylactic events in the National Electronic Injury Surveillance System. J Allergy Clin Immunol. 2008; 121:166–171.

19. James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med. 1995; 332:1262–1266.

20. Herman JJ, Radin R, Schneiderman R. Allergic reactions to measles (rubeola) vaccine in patients hypersensitive to egg protein. J Pediatr. 1983; 102:196–199.

21. Mullins R, Kemp A, Gold M. Influenza vaccination of the egg-allergic individual. Med J Aust. 2010; 193:254–255.

22. Des Roches A, Paradis L, Gagnon R, Lemire C, Begin P, Carr S, et al. Egg-allergic patients can be safely vaccinated against influenza. J Allergy Clin Immunol. 2012; 130:1213–1216.e1.

23. Yavuz ST, Sahiner UM, Sekerel BE, Tuncer A, Kalayci O, Sackesen C. Anaphylactic reactions to measles-mumps-rubella vaccine in three children with allergies to hen's egg and cow's milk. Acta Paediatr. 2011; 100:e94–e96.

24. Fischer M, Lindsey N, Staples JE, Hills S. Centers for Disease Control and Prevention (CDC). Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010; 59(RR-1):1–27.

25. Kwittken PL, Rosen S, Sweinberg SK. MMR vaccine and neomycin allergy. Am J Dis Child. 1993; 147:128–129.

26. National Center for Immunization and Respiratory Diseases. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011; 60:1–64.

27. Russell M, Pool V, Kelso JM, Tomazic-Jezic VJ. Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2004; 23:664–667.

28. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010; 59:626–629.

29. Grotto I, Mandel Y, Ephros M, Ashkenazi I, Shemer J. Major adverse reactions to yeast-derived hepatitis B vaccines: a review. Vaccine. 1998; 16:329–334.

30. DiMiceli L, Pool V, Kelso JM, Shadomy SV, Iskander J. V.A.E.R.S. Team. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine. 2006; 24:703–707.

31. Cox NH, Forsyth A. Thiomersal allergy and vaccination reactions. Contact Dermatitis. 1988; 18:229–233.

32. Zheng W, Dreskin SC. Thimerosal in influenza vaccine: an immediate hypersensitivity reaction. Ann Allergy Asthma Immunol. 2007; 99:574–575.

33. Lee-Wong M, Resnick D, Chong K. A generalized reaction to thimerosal from an influenza vaccine. Ann Allergy Asthma Immunol. 2005; 94:90–94.

34. Kattan JD, Konstantinou GN, Cox AL, Nowak-Węgrzyn A, Gimenez G, Sampson HA, et al. Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow's milk allergy. J Allergy Clin Immunol. 2011; 128:215–218.

35. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Macrophagic myofaciitis a vaccine (alum) autoimmune-related disease. Clin Rev Allergy Immunol. 2011; 41:163–168.

36. Jefferson T, Rudin M, Di Pietrantonj C. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis. 2004; 4:84–90.

37. Coors EA, Seybold H, Merk HF, Mahler V. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol. 2005; 95:593–599.

38. Badiu I, Geuna M, Heffler E, Rolla G. Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80. BMJ Case Rep. 2012; 05. 08. [Epub]. http://dx.doi.org/10.1136/bcr.02.2012.5797.

39. Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lloyd S, et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ. 2008; 179:525–533.

40. Kang LW, Crawford N, Tang ML, Buttery J, Royle J, Gold M, et al. Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study. BMJ. 2008; 337:a2642.

41. Macartney KK, Chiu C, Georgousakis M, Brotherton JM. Safety of human papillomavirus vaccines: a review. Drug Saf. 2013; 36:393–412.

42. Chang S, O'Connor PM, Slade BA, Woo EJ. U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005-2007. Vaccine. 2013; 31:1447–1452.

43. The Korean Pediatric Society. Immunization guideline. 7th ed. Seoul: The Korean Pediatric Society;2012. p. 265.

44. The Korean Pediatric Society. Immunization guideline. 7th ed. Seoul: The Korean Pediatric Society;2012. p. 18–19.

45. Zeiger RS. Current issues with influenza vaccination in egg allergy. J Allergy Clin Immunol. 2002; 110:834–840.

46. Erlewyn-Lajeunesse M, Brathwaite N, Lucas JS, Warner JO. Recommendations for the administration of influenza vaccine in children allergic to egg. BMJ. 2009; 339:b3680.

TOOLS

Similar articles